Marksans Pharma Ltd. | Mutual Funds
Mutual Funds that own Marksans Pharma Ltd.
Vanguard Emerging Markets Stock Index Fund
2,886,931
0.71%
0
0%
07/31/2018
Vanguard Total International Stock Index Fund
2,723,185
0.67%
0
0%
07/31/2018
DFA Emerging Markets Core Equity Portfolio
2,172,546
0.53%
88,970
0%
04/30/2018
1,720,571
0.42%
0
0.42%
09/05/2018
Government Pension Fund - Global (The)
1,665,103
0.41%
1,660
0%
12/31/2017
SPDR S&P Emerging Markets ETF
804,203
0.2%
0
0.03%
09/06/2018
DFA Emerging Markets Small Cap Series
747,546
0.18%
0
0.01%
01/31/2018
SPDR S&P Emerging Markets Small Cap ETF
533,954
0.13%
0
0.06%
09/06/2018
Vanguard FTSE All World (ex-US) Small Cap
444,167
0.11%
0
0%
07/31/2018
EGShares India Small Cap ETF
329,836
0.08%
0
0.9%
09/05/2018
| Address |
11th Floor Grandeur
Mumbai Maharashtra 400053
India
|
|
Employees
|
- |
| Website |
http://www.marksanspharma.com |
| Updated |
09/14/2018 |
| Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. Its product portfolio spreads over major therapeutic areas such as oncology, gastroenterology, anti-diabetic, cardiovascular, pain management, and gynecology. The company was founded by Mark Saldanha on April 16, 1992 and is headquartered in Mumbai, India. |
